Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

Chemical Validation of DegS As a Target for the Development of Antibiotics with a Novel Mode of Action.

Bongard J, Schmitz AL, Wolf A, Zischinsky G, Pieren M, Schellhorn B, Bravo-Rodriguez K, Schillinger J, Koch U, Nussbaumer P, Klebl B, Steinmann J, Buer J, Sanchez-Garcia E, Ehrmann M, Kaiser M.

ChemMedChem. 2019 Jun 5;14(11):1074-1078. doi: 10.1002/cmdc.201900193. Epub 2019 Apr 24.

PMID:
30945468
2.

Dual Inhibition of GSK3β and CDK5 Protects the Cytoskeleton of Neurons from Neuroinflammatory-Mediated Degeneration In Vitro and In Vivo.

Reinhardt L, Kordes S, Reinhardt P, Glatza M, Baumann M, Drexler HCA, Menninger S, Zischinsky G, Eickhoff J, Fröb C, Bhattarai P, Arulmozhivarman G, Marrone L, Janosch A, Adachi K, Stehling M, Anderson EN, Abo-Rady M, Bickle M, Pandey UB, Reimer MM, Kizil C, Schöler HR, Nussbaumer P, Klebl B, Sterneckert JL.

Stem Cell Reports. 2019 Mar 5;12(3):502-517. doi: 10.1016/j.stemcr.2019.01.015. Epub 2019 Feb 14.

3.

Gasdermin D plays a vital role in the generation of neutrophil extracellular traps.

Sollberger G, Choidas A, Burn GL, Habenberger P, Di Lucrezia R, Kordes S, Menninger S, Eickhoff J, Nussbaumer P, Klebl B, Krüger R, Herzig A, Zychlinsky A.

Sci Immunol. 2018 Aug 24;3(26). pii: eaar6689. doi: 10.1126/sciimmunol.aar6689.

PMID:
30143555
4.

TRPC4/TRPC5 channels mediate adverse reaction to the cancer cell cytotoxic agent (-)-Englerin A.

Cheung SY, Henrot M, Al-Saad M, Baumann M, Muller H, Unger A, Rubaiy HN, Mathar I, Dinkel K, Nussbaumer P, Klebl B, Freichel M, Rode B, Trainor S, Clapcote SJ, Christmann M, Waldmann H, Abbas SK, Beech DJ, Vasudev NS.

Oncotarget. 2018 Jul 3;9(51):29634-29643. doi: 10.18632/oncotarget.25659. eCollection 2018 Jul 3.

5.

Potent anti-leukemic activity of a specific cyclin-dependent kinase 9 inhibitor in mouse models of chronic lymphocytic leukemia.

Göthert JR, Imsak R, Möllmann M, Kesper S, Göbel M, Dührsen U, Scholz A, Lücking U, Baumann M, Unger A, Schultz-Fademrecht C, Klebl B, Eickhoff J, Choidas A, Dürig J.

Oncotarget. 2018 May 29;9(41):26353-26369. doi: 10.18632/oncotarget.25293. eCollection 2018 May 29.

6.

Combined Human Genome-wide RNAi and Metabolite Analyses Identify IMPDH as a Host-Directed Target against Chlamydia Infection.

Rother M, Gonzalez E, Teixeira da Costa AR, Wask L, Gravenstein I, Pardo M, Pietzke M, Gurumurthy RK, Angermann J, Laudeley R, Glage S, Meyer M, Chumduri C, Kempa S, Dinkel K, Unger A, Klebl B, Klos A, Meyer TF.

Cell Host Microbe. 2018 May 9;23(5):661-671.e8. doi: 10.1016/j.chom.2018.04.002. Epub 2018 Apr 26.

7.

Identification of Noncatalytic Lysine Residues from Allosteric Circuits via Covalent Probes.

Bongard J, Lorenz M, Vetter IR, Stege P, Porfetye AT, Schmitz AL, Kaschani F, Wolf A, Koch U, Nussbaumer P, Klebl B, Kaiser M, Ehrmann M.

ACS Chem Biol. 2018 May 18;13(5):1307-1312. doi: 10.1021/acschembio.8b00101. Epub 2018 Apr 16.

PMID:
29658704
8.

Dynarrestin, a Novel Inhibitor of Cytoplasmic Dynein.

Höing S, Yeh TY, Baumann M, Martinez NE, Habenberger P, Kremer L, Drexler HCA, Küchler P, Reinhardt P, Choidas A, Zischinsky ML, Zischinsky G, Nandini S, Ledray AP, Ketcham SA, Reinhardt L, Abo-Rady M, Glatza M, King SJ, Nussbaumer P, Ziegler S, Klebl B, Schroer TA, Schöler HR, Waldmann H, Sterneckert J.

Cell Chem Biol. 2018 Apr 19;25(4):357-369.e6. doi: 10.1016/j.chembiol.2017.12.014. Epub 2018 Jan 27.

9.

Identification of an (-)-englerin A analogue, which antagonizes (-)-englerin A at TRPC1/4/5 channels.

Rubaiy HN, Seitz T, Hahn S, Choidas A, Habenberger P, Klebl B, Dinkel K, Nussbaumer P, Waldmann H, Christmann M, Beech DJ.

Br J Pharmacol. 2018 Mar;175(5):830-839. doi: 10.1111/bph.14128. Epub 2018 Jan 25.

10.

Identification of Atuveciclib (BAY 1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of Cancer.

Lücking U, Scholz A, Lienau P, Siemeister G, Kosemund D, Bohlmann R, Briem H, Terebesi I, Meyer K, Prelle K, Denner K, Bömer U, Schäfer M, Eis K, Valencia R, Ince S, von Nussbaum F, Mumberg D, Ziegelbauer K, Klebl B, Choidas A, Nussbaumer P, Baumann M, Schultz-Fademrecht C, Rühter G, Eickhoff J, Brands M.

ChemMedChem. 2017 Nov 8;12(21):1776-1793. doi: 10.1002/cmdc.201700447. Epub 2017 Oct 16.

11.

Systematic Kinase Inhibitor Profiling Identifies CDK9 as a Synthetic Lethal Target in NUT Midline Carcinoma.

Brägelmann J, Dammert MA, Dietlein F, Heuckmann JM, Choidas A, Böhm S, Richters A, Basu D, Tischler V, Lorenz C, Habenberger P, Fang Z, Ortiz-Cuaran S, Leenders F, Eickhoff J, Koch U, Getlik M, Termathe M, Sallouh M, Greff Z, Varga Z, Balke-Want H, French CA, Peifer M, Reinhardt HC, Örfi L, Kéri G, Ansén S, Heukamp LC, Büttner R, Rauh D, Klebl BM, Thomas RK, Sos ML.

Cell Rep. 2017 Sep 19;20(12):2833-2845. doi: 10.1016/j.celrep.2017.08.082.

12.

Discovery of a Novel Inhibitor of the Hedgehog Signaling Pathway through Cell-based Compound Discovery and Target Prediction.

Kremer L, Schultz-Fademrecht C, Baumann M, Habenberger P, Choidas A, Klebl B, Kordes S, Schöler HR, Sterneckert J, Ziegler S, Schneider G, Waldmann H.

Angew Chem Int Ed Engl. 2017 Oct 9;56(42):13021-13025. doi: 10.1002/anie.201707394. Epub 2017 Sep 18.

PMID:
28833911
13.

Professional translational research: a new hybrid paradigm in early drug discovery.

Nussbaumer P, Klebl B.

Future Med Chem. 2015;7(14):1879-89. doi: 10.4155/fmc.15.124. Epub 2015 Sep 30.

14.

A novel CDK7 inhibitor of the Pyrazolotriazine class exerts broad-spectrum antiviral activity at nanomolar concentrations.

Hutterer C, Eickhoff J, Milbradt J, Korn K, Zeitträger I, Bahsi H, Wagner S, Zischinsky G, Wolf A, Degenhart C, Unger A, Baumann M, Klebl B, Marschall M.

Antimicrob Agents Chemother. 2015 Apr;59(4):2062-71. doi: 10.1128/AAC.04534-14. Epub 2015 Jan 26.

15.

Cyclin-dependent kinase 7 controls mRNA synthesis by affecting stability of preinitiation complexes, leading to altered gene expression, cell cycle progression, and survival of tumor cells.

Kelso TW, Baumgart K, Eickhoff J, Albert T, Antrecht C, Lemcke S, Klebl B, Meisterernst M.

Mol Cell Biol. 2014 Oct 1;34(19):3675-88. doi: 10.1128/MCB.00595-14. Epub 2014 Jul 21.

16.

The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells.

Paolino M, Choidas A, Wallner S, Pranjic B, Uribesalgo I, Loeser S, Jamieson AM, Langdon WY, Ikeda F, Fededa JP, Cronin SJ, Nitsch R, Schultz-Fademrecht C, Eickhoff J, Menninger S, Unger A, Torka R, Gruber T, Hinterleitner R, Baier G, Wolf D, Ullrich A, Klebl BM, Penninger JM.

Nature. 2014 Mar 27;507(7493):508-12. doi: 10.1038/nature12998. Epub 2014 Feb 19.

17.

Characterization of molecular and cellular functions of the cyclin-dependent kinase CDK9 using a novel specific inhibitor.

Albert TK, Rigault C, Eickhoff J, Baumgart K, Antrecht C, Klebl B, Mittler G, Meisterernst M.

Br J Pharmacol. 2014 Jan;171(1):55-68. doi: 10.1111/bph.12408.

18.

Amorfrutins are potent antidiabetic dietary natural products.

Weidner C, de Groot JC, Prasad A, Freiwald A, Quedenau C, Kliem M, Witzke A, Kodelja V, Han CT, Giegold S, Baumann M, Klebl B, Siems K, Müller-Kuhrt L, Schürmann A, Schüler R, Pfeiffer AF, Schroeder FC, Büssow K, Sauer S.

Proc Natl Acad Sci U S A. 2012 May 8;109(19):7257-62. doi: 10.1073/pnas.1116971109. Epub 2012 Apr 16.

19.

Recruitment of cyclin-dependent kinase 9 to nuclear compartments during cytomegalovirus late replication: importance of an interaction between viral pUL69 and cyclin T1.

Feichtinger S, Stamminger T, Müller R, Graf L, Klebl B, Eickhoff J, Marschall M.

J Gen Virol. 2011 Jul;92(Pt 7):1519-31. doi: 10.1099/vir.0.030494-0. Epub 2011 Mar 30.

PMID:
21450947
20.

Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer.

Weiss J, Sos ML, Seidel D, Peifer M, Zander T, Heuckmann JM, Ullrich RT, Menon R, Maier S, Soltermann A, Moch H, Wagener P, Fischer F, Heynck S, Koker M, Schöttle J, Leenders F, Gabler F, Dabow I, Querings S, Heukamp LC, Balke-Want H, Ansén S, Rauh D, Baessmann I, Altmüller J, Wainer Z, Conron M, Wright G, Russell P, Solomon B, Brambilla E, Brambilla C, Lorimier P, Sollberg S, Brustugun OT, Engel-Riedel W, Ludwig C, Petersen I, Sänger J, Clement J, Groen H, Timens W, Sietsma H, Thunnissen E, Smit E, Heideman D, Cappuzzo F, Ligorio C, Damiani S, Hallek M, Beroukhim R, Pao W, Klebl B, Baumann M, Buettner R, Ernestus K, Stoelben E, Wolf J, Nürnberg P, Perner S, Thomas RK.

Sci Transl Med. 2010 Dec 15;2(62):62ra93. doi: 10.1126/scitranslmed.3001451. Erratum in: Sci Transl Med. 2011 Jan 19;3(66):66er2. Sci Transl Med. 2012 Apr 18;4(130):130er2.

21.

A flexible multiwell format for immunofluorescence screening microscopy of small-molecule inhibitors.

Scholz AK, Klebl BM, Morkel M, Lehrach H, Dahl A, Lange BM.

Assay Drug Dev Technol. 2010 Oct;8(5):571-80. doi: 10.1089/adt.2009.0260. Epub 2010 Jul 28.

PMID:
20666660
22.

Small-molecule inhibitors binding to protein kinase. Part II: the novel pharmacophore approach of type II and type III inhibition.

Backes A, Zech B, Felber B, Klebl B, Müller G.

Expert Opin Drug Discov. 2008 Dec;3(12):1427-49. doi: 10.1517/17460440802580106.

PMID:
23506107
23.

Small-molecule inhibitors binding to protein kinases. Part I: exceptions from the traditional pharmacophore approach of type I inhibition.

Backes A, Zech B, Felber B, Klebl B, Müller G.

Expert Opin Drug Discov. 2008 Dec;3(12):1409-25. doi: 10.1517/17460440802579975.

PMID:
23506106
24.

Signalling inhibitors against Mycobacterium tuberculosis--early days of a new therapeutic concept in tuberculosis.

Hegymegi-Barakonyi B, Székely R, Varga Z, Kiss R, Borbély G, Németh G, Bánhegyi P, Pató J, Greff Z, Horváth Z, Mészáros G, Marosfalvi J, Erōs D, Szántai-Kis C, Breza N, Garavaglia S, Perozzi S, Rizzi M, Hafenbradl D, Ko M, Av-Gay Y, Klebl BM, Orfi L, Kéri G.

Curr Med Chem. 2008;15(26):2760-70.

PMID:
18991635
25.

Protein kinase inhibitors of the quinazoline class exert anti-cytomegaloviral activity in vitro and in vivo.

Schleiss M, Eickhoff J, Auerochs S, Leis M, Abele S, Rechter S, Choi Y, Anderson J, Scott G, Rawlinson W, Michel D, Ensminger S, Klebl B, Stamminger T, Marschall M.

Antiviral Res. 2008 Jul;79(1):49-61. doi: 10.1016/j.antiviral.2008.01.154. Epub 2008 Feb 22.

PMID:
18329738
26.

A novel drug discovery concept for tuberculosis: inhibition of bacterial and host cell signalling.

Székely R, Wáczek F, Szabadkai I, Németh G, Hegymegi-Barakonyi B, Eros D, Szokol B, Pató J, Hafenbradl D, Satchell J, Saint-Joanis B, Cole ST, Orfi L, Klebl BM, Kéri G.

Immunol Lett. 2008 Mar 15;116(2):225-31. doi: 10.1016/j.imlet.2007.12.005. Epub 2008 Jan 8.

PMID:
18258308
27.

An RNA molecule that specifically inhibits G-protein-coupled receptor kinase 2 in vitro.

Mayer G, Wulffen B, Huber C, Brockmann J, Flicke B, Neumann L, Hafenbradl D, Klebl BM, Lohse MJ, Krasel C, Blind M.

RNA. 2008 Mar;14(3):524-34. doi: 10.1261/rna.821908. Epub 2008 Jan 29.

28.

Gleevec increases levels of the amyloid precursor protein intracellular domain and of the amyloid-beta degrading enzyme neprilysin.

Eisele YS, Baumann M, Klebl B, Nordhammer C, Jucker M, Kilger E.

Mol Biol Cell. 2007 Sep;18(9):3591-600. Epub 2007 Jul 11.

29.

Drug discovery in the kinase inhibitory field using the Nested Chemical Library technology.

Kéri G, Székelyhidi Z, Bánhegyi P, Varga Z, Hegymegi-Barakonyi B, Szántai-Kis C, Hafenbradl D, Klebl B, Muller G, Ullrich A, Erös D, Horváth Z, Greff Z, Marosfalvi J, Pató J, Szabadkai I, Szilágyi I, Szegedi Z, Varga I, Wáczek F, Orfi L.

Assay Drug Dev Technol. 2005 Oct;3(5):543-51. Review.

PMID:
16305311
30.

Second-generation kinase inhibitors.

Klebl BM, Müller G.

Expert Opin Ther Targets. 2005 Oct;9(5):975-93. Review.

PMID:
16185153
31.

Role of protein kinase G in growth and glutamine metabolism of Mycobacterium bovis BCG.

Nguyen L, Walburger A, Houben E, Koul A, Muller S, Morbitzer M, Klebl B, Ferrari G, Pieters J.

J Bacteriol. 2005 Aug;187(16):5852-6. Erratum in: J Bacteriol. 2005 Oct;187(20):7165.

32.

Synthesis of selective SRPK-1 inhibitors: novel tricyclic quinoxaline derivatives.

Székelyhidi Z, Pató J, Wáczek F, Bánhegyi P, Hegymegi-Barakonyi B, Erös D, Mészáros G, Hollósy F, Hafenbradl D, Obert S, Klebl B, Kéri G, Orfi L.

Bioorg Med Chem Lett. 2005 Jul 1;15(13):3241-6.

PMID:
15925511
33.

Host cell targets in HCV therapy: novel strategy or proven practice?

Klebl BM, Kurtenbach A, Salassidis K, Daub H, Herget T.

Antivir Chem Chemother. 2005;16(2):69-90. Review.

PMID:
15889531
34.

Advances in anti-viral therapeutics.

Klebl BM.

Expert Opin Investig Drugs. 2005 Mar;14(3):343-8.

PMID:
15833066
35.

Cellular targets of gefitinib.

Brehmer D, Greff Z, Godl K, Blencke S, Kurtenbach A, Weber M, Müller S, Klebl B, Cotten M, Kéri G, Wissing J, Daub H.

Cancer Res. 2005 Jan 15;65(2):379-82.

36.

Chemical kinomics - a target gene family approach in chemical biology.

Klebl BM.

Drug Discov Today Technol. 2004 Sep;1(1):25-34. doi: 10.1016/j.ddtec.2004.08.013.

PMID:
24981264
37.

Screening assay for the identification of deoxyhypusine synthase inhibitors.

Sommer MN, Bevec D, Klebl B, Flicke B, Hölscher K, Freudenreich T, Hauber I, Hauber J, Mett H.

J Biomol Screen. 2004 Aug;9(5):434-8.

PMID:
15296643
38.

The tyrosine kinase inhibitor STI571 induces cellular clearance of PrPSc in prion-infected cells.

Ertmer A, Gilch S, Yun SW, Flechsig E, Klebl B, Stein-Gerlach M, Klein MA, Schätzl HM.

J Biol Chem. 2004 Oct 1;279(40):41918-27. Epub 2004 Jul 9.

39.

Evaluation of kinase inhibitor selectivity by chemical proteomics.

Daub H, Godl K, Brehmer D, Klebl B, Müller G.

Assay Drug Dev Technol. 2004 Apr;2(2):215-24. Review.

PMID:
15165517
40.

Protein kinase G from pathogenic mycobacteria promotes survival within macrophages.

Walburger A, Koul A, Ferrari G, Nguyen L, Prescianotto-Baschong C, Huygen K, Klebl B, Thompson C, Bacher G, Pieters J.

Science. 2004 Jun 18;304(5678):1800-4. Epub 2004 May 20.

41.

Interplay between mycobacteria and host signalling pathways.

Koul A, Herget T, Klebl B, Ullrich A.

Nat Rev Microbiol. 2004 Mar;2(3):189-202. Review. No abstract available.

PMID:
15083155
42.

Stacking up the armory against viruses.

Klebl BM.

Drug Discov Today. 2004 Feb 15;9(4):162-4. No abstract available.

PMID:
14960395
43.

RICK activates a NF-kappaB-dependent anti-human cytomegalovirus response.

Eickhoff J, Hanke M, Stein-Gerlach M, Kiang TP, Herzberger K, Habenberger P, Müller S, Klebl B, Marschall M, Stamminger T, Cotten M.

J Biol Chem. 2004 Mar 5;279(10):9642-52. Epub 2003 Dec 10.

44.

Generation of conditional lethal Candida albicans mutants by inducible deletion of essential genes.

Michel S, Ushinsky S, Klebl B, Leberer E, Thomas D, Whiteway M, Morschhäuser J.

Mol Microbiol. 2002 Oct;46(1):269-80.

45.

A comprehensive analysis of gene expression profiles in a yeast N-glycosylation mutant.

Klebl B, Kozian D, Leberer E, Kukuruzinska MA.

Biochem Biophys Res Commun. 2001 Aug 31;286(4):714-20.

PMID:
11520056
46.

A role for myosin-I in actin assembly through interactions with Vrp1p, Bee1p, and the Arp2/3 complex.

Evangelista M, Klebl BM, Tong AH, Webb BA, Leeuw T, Leberer E, Whiteway M, Thomas DY, Boone C.

J Cell Biol. 2000 Jan 24;148(2):353-62.

48.

Specificity and target proteins of arginine-specific mono-ADP-ribosylation in T-tubules of rabbit skeletal muscle.

Klebl BM, Göpel SO, Pette D.

Arch Biochem Biophys. 1997 Nov 15;347(2):155-62.

PMID:
9367520
49.

A fluorometric assay for measurement of mono-ADP-ribosyltransferase activity.

Klebl BM, Pette D.

Anal Biochem. 1996 Aug 1;239(2):145-52.

PMID:
8811894
50.

Supplemental Content

Support Center